Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
LONDON - EKF Diagnostics Holdings plc (AIM:EKF), a global diagnostics business, purchased 410,344 of its ordinary shares at a weighted average price of 25.89 pence per share on October 28, according to a company press release issued Wednesday.
The repurchased shares will be held in treasury. The company executed the buyback in three separate transactions on the London Stock Exchange’s AIM market, with purchase prices ranging from 25.85 pence to 26.20 pence per share.
As part of the buyback, EKF acquired 121,000 ordinary shares from Harwood, which acted as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC. This transaction was facilitated to ensure that the aggregate indirect beneficial interest of Christopher Mills, a Non-Executive Director, remains at approximately the same level and does not exceed 30% of the company’s total voting rights.
Following the share repurchase, EKF’s total issued share capital consists of 449,093,790 ordinary shares, with 5,675,252 shares held in treasury. The total number of ordinary shares carrying voting rights will be 443,418,538.
EKF Diagnostics is focused on point-of-care analyzers in hematology and diabetes, as well as life sciences services providing specialized manufacture of enzymes and custom products. The company operates five manufacturing sites across the US and Germany and sells into over 120 countries worldwide.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.